Thomas Littlejohn

1.8k total citations
43 papers, 1.4k citations indexed

About

Thomas Littlejohn is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Thomas Littlejohn has authored 43 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cardiology and Cardiovascular Medicine, 17 papers in Surgery and 12 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Thomas Littlejohn's work include Blood Pressure and Hypertension Studies (20 papers), Hormonal Regulation and Hypertension (8 papers) and Cardiovascular Syncope and Autonomic Disorders (7 papers). Thomas Littlejohn is often cited by papers focused on Blood Pressure and Hypertension Studies (20 papers), Hormonal Regulation and Hypertension (8 papers) and Cardiovascular Syncope and Autonomic Disorders (7 papers). Thomas Littlejohn collaborates with scholars based in United States, United Kingdom and Germany. Thomas Littlejohn's co-authors include Sherwyn Schwartz, Steven G. Chrysant, James M. McKenney, Christine McCrary Sisk, Diane L. Tribble, Yale Mitchel, Daniel M. Bloomfield, Claudio Majul, Mary Seeber and Gary L. Carlson and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and CHEST Journal.

In The Last Decade

Thomas Littlejohn

41 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Littlejohn United States	22	607	601	392	222	222	43	1.4k
Joel Neutel United States	20	1.1k 1.9×	554 0.9×	518 1.3×	215 1.0×	118 0.5×	48	1.9k
Matilda Florentin Greece	24	274 0.5×	584 1.0×	719 1.8×	255 1.1×	164 0.7×	73	1.7k
Sergio D’Addato Italy	27	478 0.8×	361 0.6×	434 1.1×	296 1.3×	91 0.4×	90	1.8k
Harry Haber United States	16	1.3k 2.1×	700 1.2×	672 1.7×	236 1.1×	148 0.7×	28	2.2k
Amar A Sethi Denmark	20	550 0.9×	950 1.6×	833 2.1×	340 1.5×	85 0.4×	26	1.7k
Giovanni Battista Vigna Italy	21	397 0.7×	479 0.8×	806 2.1×	202 0.9×	67 0.3×	55	1.5k
Amber L. Beitelshees United States	26	733 1.2×	721 1.2×	269 0.7×	642 2.9×	124 0.6×	90	2.0k
Jin‐Jer Chen Taiwan	19	504 0.8×	274 0.5×	175 0.4×	310 1.4×	115 0.5×	55	1.4k
Emily K Marino United States	7	1.0k 1.7×	804 1.3×	932 2.4×	205 0.9×	88 0.4×	9	2.6k
Cecilia C. Low Wang United States	14	457 0.8×	866 1.4×	443 1.1×	430 1.9×	103 0.5×	39	1.8k

Countries citing papers authored by Thomas Littlejohn

Since Specialization

Citations

This map shows the geographic impact of Thomas Littlejohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Littlejohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Littlejohn more than expected).

Fields of papers citing papers by Thomas Littlejohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Littlejohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Littlejohn. The network helps show where Thomas Littlejohn may publish in the future.

Co-authorship network of co-authors of Thomas Littlejohn

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Littlejohn. A scholar is included among the top collaborators of Thomas Littlejohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Littlejohn. Thomas Littlejohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kereiakes, Dean J., Steven G. Chrysant, Joseph L. Izzo, et al.. (2012). Long‐Term Efficacy and Safety of Triple‐Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension. Journal of Clinical Hypertension. 14(3). 149–157. 16 indexed citations

Sharma, Arya M., et al.. (2012). Single-Pill Combination of Telmisartan/Amlodipine Versus Amlodipine Monotherapy in Diabetic Hypertensive Patients: An 8-Week Randomized, Parallel-Group, Double-Blind Trial. Clinical Therapeutics. 34(3). 537–551. 18 indexed citations

Kereiakes, Dean J., Steven G. Chrysant, Joseph L. Izzo, et al.. (2012). Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovascular Diabetology. 11(1). 134–134. 22 indexed citations

Chrysant, Steven G., Thomas Littlejohn, Joseph L. Izzo, et al.. (2012). Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension. American Journal of Cardiovascular Drugs. 12(4). 233–243. 18 indexed citations

Littlejohn, Thomas, et al.. (2012). Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study. Journal of Human Hypertension. 27(5). 321–327. 13 indexed citations

Dansky, Hayes M., Daniel M. Bloomfield, Patrice H. Gibbons, et al.. (2011). Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. American Heart Journal. 162(4). 708–716. 24 indexed citations

Izzo, Joseph L., Steven G. Chrysant, Dean J. Kereiakes, et al.. (2011). 24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy. Journal of Clinical Hypertension. 13(12). 873–880. 30 indexed citations

Ram, C. Venkata S., et al.. (2011). Management of Hypertension in Patients With Diabetes Using an Amlodipine-, Olmesartan Medoxomil-, and Hydrochlorothiazide-Based Titration Regimen. The American Journal of Cardiology. 107(9). 1346–1352. 24 indexed citations

Littlejohn, Thomas, et al.. (2009). Results of Treatment With Telmisartan‐Amlodipine in Hypertensive Patients. Journal of Clinical Hypertension. 11(4). 207–213. 72 indexed citations

10.

Littlejohn, Thomas, et al.. (2009). Original Research: Telmisartan plus Amlodipine in Patients with Moderate or Severe Hypertension: Results from a Subgroup Analysis of a Randomized, Placebo-Controlled, Parallel-Group, 4 × 4 Factorial Study. Postgraduate Medicine. 121(2). 5–14. 51 indexed citations

11.

González-Gálvez, Guillermo, Thomas Littlejohn, Sherwyn Schwartz, et al.. (2008). The dipeptidyl peptidase‐4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 10(4). 293–300. 25 indexed citations

12.

MacDonald, Thomas M., Jean‐Yves Reginster, Thomas Littlejohn, et al.. (2008). Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. Journal of Hypertension. 26(8). 1695–1702. 19 indexed citations

13.

Bloomfield, Daniel M., Gary L. Carlson, Aditi Sapre, et al.. (2008). Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. American Heart Journal. 157(2). 352–360.e2. 184 indexed citations

14.

Neutel, Joel M., Thomas Littlejohn, Steven G. Chrysant, & Ashish Singh. (2005). Telmisartan/Hydrochlorothiazide in Comparison with Losartan/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate Hypertension. Hypertension Research. 28(7). 555–563. 45 indexed citations

15.

Shepherd, James, Chris J. Packard, Thomas Littlejohn, et al.. (2004). Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy*. Current Medical Research and Opinion. 20(10). 1571–1578. 10 indexed citations

16.

Castell, D. O., David Silvers, Thomas Littlejohn, et al.. (1999). Cisapride 20 mg b.d. for preventing symptoms of GERD induced by a provocative meal. Alimentary Pharmacology & Therapeutics. 13(6). 787–794. 11 indexed citations

17.

Hall, Wayne, et al.. (1998). Efficacy and Tolerability of Valsartan in Combination with Hydrochlorothiazide in Essential Hypertension. Clinical Drug Investigation. 16(3). 203–210. 25 indexed citations

18.

Tack, Kenneth J., et al.. (1998). Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. Clinical Therapeutics. 20(2). 244–256. 28 indexed citations

19.

Bagel, Jerry, Debra Breneman, Michael F. Holick, et al.. (1998). Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial. Journal of the American Academy of Dermatology. 38(6). 938–944. 73 indexed citations

20.

Littlejohn, Thomas, et al.. (1996). Brompheniramine, Terfenadine, and Placebo in Allergic Rhinitis. Annals of Allergy Asthma & Immunology. 77(5). 365–370. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact